Plain-English translation of NCT06301841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether two special laboratory tests—a rapid multiplex PCR test that identifies many bacteria and viruses, and a procalcitonin blood test—can help doctors decide when to stop antibiotics sooner in patients with COPD and pneumonia. Right now, doctors often give antibiotics for longer than needed because they're not sure when it's safe to stop. This study compares the standard approach to using these new tests to make smarter, faster decisions.
Patients on long antibiotic courses face risks like side effects and resistant bacteria developing. This trial exists to see whether the new treatment approach can reduce unnecessary antibiotic exposure while keeping patients safe.
You likely qualify if…
You likely don't qualify if…
You would be admitted to the ICU and randomly assigned to either the standard treatment group or the new testing group. All patients start antibiotics immediately as usual. If you're in the new testing group, doctors will collect a respiratory sample and do a rapid multiplex PCR test on day one, plus check your procalcitonin level on day three. Based on these results, your doctors can decide whether to keep or stop your antibiotics. The study tracks how many days of antibiotics you receive and how you recover.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France